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Abstract 
Drug development represents a highly complex, inefficient and costly process. Over the past decade, the 
widespread use of nuclear imaging, owing to its functional and molecular nature, has proven to be a 
determinant in improving the efficiency in selecting the candidate drugs that should either be abandoned 
or moved forward into clinical trials. This helps not only with the development of safer and effective 
drugs but also with the shortening of time-to-market. The modern concept and future trends concerning 
molecular imaging will assumedly be hybrid or multimodality imaging, including combinations between 
high sensitivity and functional (molecular) modalities with high spatial resolution and morphological 
techniques. 
 
Introduction 
The discovery and development of new drugs is perhaps one of the most challenging activities driven by 
the scientific community and simultaneously one of the most expensive and time consuming. On average, 
the cycle of bringing a new drug to market can last between 5 and 10 years (with around 8 years being 
typical), costing more than US$1 billion. Drug development is a rather inefficient process, because only 
one in 5000 tested compounds will reach the market 3 and 4. Owing to the dimension of the involved 
investment, all stakeholders (pharmaceutical companies, physicians and patients) want effective drugs to 
be developed and become widely available at a reasonable cost. To achieve this, mechanisms of disease 
need to be well understood and the compounds to be tested need to be well characterized in the early phases 
of research, those that generally are less costly. In this review we will provide an overview of: (i) the main 
steps of drug development and its related challenges; as well as (ii) the role and potential of molecular 
imaging and how it might contribute to improving the overall efficiency of the process. 
Stages of drug development 
The process of drug development comprises five stages, characterized by specific objectives, using a set of 
resources (Fig. 1). The decision to undertake the process of developing a new drug is usually triggered by 
the need to treat a pathological condition presenting an unsatisfactory response to the existing drugs. 
 
Figure 1. Phases of drug development and the respective main objectives. Solid circles highlight the 
phases where molecular imaging is most useful. 
 
Target identification and validation 
The first step involves target selection and usually requires a solid knowledge of the underlying 
pathophysiological processes to do it in a timely fashion. The sequencing of the human genome (as well as 
those of many pathogens) has broadened the number of potential drug targets in the past decade. A drug 
target can be a membrane or a nuclear receptor, an ion channel, an enzyme, a hormone, DNA or RNA 
molecules, or an unidentified biological entity. At this phase, molecular imaging has proven to be useful in 
detecting the presence of drug targets, their spatial and temporal distribution and the functional 
consequences of drug target interaction. Nuclear imaging modalities and positron emission tomography 
(PET) in particular are being increasingly widely used for the study of receptor expression and occupancy 
in central nervous system drug development 7 and 8, as shown in Fig. 2, which illustrates the use of two 
different brain receptor antagonists (i.e. 11C-raclopride for dopamine D2 receptors and 125I-SD7015 for 
cannabinoid-1 receptor) to obtain qualitative and quantitative data about receptor occupancy over time. 
 
 Figure 2. Receptor binding quantification by nuclear imaging modalities. (a) Dynamic positron emission 
tomography (PET) list mode images obtained (NanoScan, Mediso, Hungary) from a male Wistar rat, 
after the intravenous injection of 12.0 MBq of 11C-raclopride, a dopamine D2 receptor ligand. 
Transverse slices of the rat brain are shown: T2-weighted magnetic resonance (MR) images showing 
anatomic detailed information and PET images acquired 75–90 min post injection showing receptor D2 
receptor binding. (b) After the delineation of three volumes of interest (VOI) in the striata (exhibiting the 
highest receptor expression, 150 fmol/mg tissue), cortex (moderate receptor expression) and cerebellum 
(control tissue with no receptor expression), radioactivity in kiloBecquerel per cubic centimeter (kBq/cc) 
was quantitatively determined in the PET images. Region volumes were determined by MR images. The 
time–activity curves represent tracer concentration over time. Kinetic D2-receptor binding constants can 
be then derived from the data. (c) Brain coronal images of a C57BI6 male mouse acquired after the 
intravenous administration of 1.40 MBq of a central cannabinoid-1 receptor (CB1R) ligand, 125I-SD7015. 
On the left, single-photon emission computed tomography and computed tomography (SPECT/CT) image, 
acquired 3 h after tracer injection (NanoSPECT/CT Silver Upgrade, Mediso, Hungary) is shown. Images 
were then co-registered with a magnetic resonance imaging (MRI) atlas using nonlinear co-registration 
software (Fusion, Mediso, Hungary). On the right, the corresponding thin-slice autoradiography coronal 
section from the brain is depicted, with CB1R-rich regions such as hippocampus, cortical region and the 
substantia nigra showing increased uptake in the grayscale image. 
 
An alternative to the direct approach of target imaging (often a complex and time-consuming process) 
would be the use of reporter genes. A variety of reporter genes have been developed for optical, magnetic 
resonance and nuclear imaging. Reporter genes are useful in the evaluation of the levels of expression of 
specific genes as well as several intracellular biologic processes, such as signal transduction pathways, 
nuclear receptor activities and protein–protein interactions. During recent years, reporter gene imaging 
techniques have emerged as excellent tools, not only for drug target interaction monitoring but also for 
therapy evaluation. 
Lead finding and optimization 
After being identified and validated, the drug target is exposed to a large number of compounds and 
analyzed by biochemical and cellular assays compatible with automated high-throughput screening 4 and 6. 
In this phase, relevant parameters are evaluated, such as compound purity, integrity, solubility, lipophilicity, 
safety, dissociation constant, permeability and target affinity. Furthermore, compound analogs can be 
synthesized and tested to identify those exhibiting better responses in more complex models (leads), which 
are then optimized and pursued for preclinical testing. Moreover, in vitro optical imaging (OI) can be useful 
at this stage for compound screening in cell-based assays owing to its high sensitivity, low cost and high-
throughput capabilities. 
Compound profiling in animal models 
In this phase, in vivo imaging techniques using relevant animal models of disease play an important part, 
providing valuable information concerning drug absorption, distribution, metabolism, elimination (ADME) 
and efficacy. Usually, to study the pharmacodynamics and biodistribution properties of a candidate drug, 
the drug itself is labeled with an imaging probe (e.g. a radionuclide, a fluorophore metal with high 
relaxivity). A great advantage of this approach is that it requires only a minimal number of animals 
(compliant with the 3Rs policy, see Box 1), which can be imaged repeatedly for longitudinal studies, in 
direct contrast to the more conventional destructive biodistribution approaches, in which animals are 
sacrificed at predefined timepoints, thus requiring larger amounts of animals (even if traditional 
pharmacokinetic methods are not totally replaceable by imaging). 
 
 
 
Usually, longitudinal imaging results not only in lower cost but also more-reliable results, because 
intersubject variability is higher than test–retest intrasubject measurement results. Rodents are the most 
commonly used living animals for preclinical imaging studies and mice have been particularly important 
for a number of reasons: the genetic similarities with humans; the availability and diversity of genetically 
modified strains and disease models; and the lower amounts of compound required for testing compared 
with higher species. Preclinical imaging establishes a relationship between findings at the molecular level 
and clinical observations with the application of the same candidate entities. This is vital for the success of 
the subsequent phases because the role of a molecule in a disease model in vitro might not mimic its role 
and molecular interactions in vivo. Imaging techniques based on the in vivo biomarker readout concept 
anticipate decision making regarding compound safety and efficacy, leading to significant cost reductions 
by shortening the time to market and by eliminating poor candidate drugs earlier in the development process 
14 and 15. In fact, through the use of functional imaging, it is possible to determine whether the target can 
be modulated by an external therapeutic chemical compound and if the concentration of drug reaching the 
target is sufficient to induce the desired therapeutic effect and does not accumulate in non-target organs, 
potentially inducing toxicity. If that is not the case, then research will be directed to other promising 
candidates, potentially leading to consequent financial and time savings. A possible example could be the 
case of a drug designed to have antiangiogenic properties, cutting-off tumor blood supply. Imaging would 
lead to evaluating not only the tumor size but also other important aspects such as tumor blood supply, 
oxygen consumption, tumor metabolism, tumor shrinkage or scaring. In fact, imaging techniques can 
provide not only qualitative but also quantitative data with rather good precision levels and reproducibility, 
being of paramount importance in go–no-go decisions. From the ethical perspective, it is indeed important 
to spare the patient from exposure to experimental drugs with little or no therapeutic effect. However, before 
final conclusions are drawn, researchers must be aware that, despite genetic similarities, animal models 
might not represent the full phenotype of human physiology for many reasons, for example differences in 
membrane transporter proteins. In addition, before clinical testing, the toxicity profile of the drug must be 
characterized using two or more animal species (usually one rodent and one non-rodent) because the drug 
might affect species differently. Imaging can also play a part in the determination of the amount of the drug 
that remains in the circulation, the amount that is taken up by the different organs, how much is broken 
down and the resultant metabolites and its excretion from the body. In the literature, there are a few 
examples of toxicity studies where the contribution of imaging was valuable, for example the paper by 
Zhang et al. that studies the effects of anesthetics in developing brains using biomarkers of apoptosis (18F-
annexin-V), brain metabolism (2-deoxy-2-[18F]-fluoro-D-glucose, 18F-FDG), neuroinflammation [18F-(N-
(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide), 18F-FEPPA] and cell proliferation (3’-
deoxy-3’-[18F]-fluoro-L-thymidine, 18F-FLT). 
Safety evaluation 
Drug safety can be assessed either in vivo or ex vivo, aiming to characterize the toxicological effects on 
organ function and structure. In the past during this stage in vivo imaging was not widely used, possibly 
because toxicological studies must be carried out in compliance with good laboratory practice (GLP) 
guidelines. Because these conditions are not always common in standard animal imaging laboratories, the 
use of imaging for toxicological studies might require separate installations or separate groups of animals. 
Importantly, in the discovery phases, information from animal studies is crucial for the determination of 
the proper dose to be tested in the clinical trials; thus, in recent years, some pharmaceutical companies have 
established their own imaging laboratories. 
Clinical evaluation 
Once the drug candidate safety has been established for human administration, clinical studies can be 
launched, providing that authorization by a regulatory agency [e.g. FDA or European Medicines Agency 
(EMA)] has been given. They are divided into four sequential phases (I–IV), although more recently 
regulatory agencies approved the so-called ‘Phase 0’ trials, which are held with a very small group of 
individuals prior to Phase I, aiming to provide pharmacokinetic data and target interaction in humans. In 
this phase, very low doses (typically 100 times less than the intended therapeutic dose) of drug candidates 
are used, without any intended therapeutic purposes, to determine whether the compound has appropriate 
pharmacokinetic and pharmacodynamic profiles in humans. Often, compounds can be labeled with a 
suitable radionuclide and image acquisition (PET, for instance) can thus be performed. Potentially, this 
phase can help in eliminating poor candidate drugs before they reach Phase I, once again contributing to 
time sparing and cost reduction, thus improving the overall efficiency of the drug development process. In 
Phase I, the drug is tested in healthy volunteers (typically 20–80) to evaluate pharmacokinetics and safe 
dose range 4 and 6. In the case of some oncology agents, studies can be performed in patients to verify 
whether pharmacological effects observed in animals are reproduced in humans. Usually, they are critically 
ill patients or have a terminal disease and have tried the conventional therapeutic options. Because some of 
these patients might benefit from the new treatment, sometimes they are included in the trials after careful 
consideration of the risk:benefit ratio. These studies can result in go–no-go decisions based on parameters 
such as safety, tolerability and pharmacokinetic and pharmacodynamic properties of the candidate drug. 
Approximately two-thirds of Phase I compounds will be found safe enough to progress to Phase II, which 
is carried out to provide a well-controlled and detailed assessment of the drug's safety and therapeutic 
efficacy in a larger population. Moreover, dose regimens (i.e. dosing interval, method of delivery: e.g. oral 
and intravenous) to be administered to the target population in Phase III are tested at Phase II. Determining 
the optimal dose (i.e. the one inducing the maximum therapeutic effect with minimal side effects) is of the 
utmost importance. Once again, results from Phase II can lead to go–no-go decisions based on criteria such 
as drug effectiveness, safety and observed side effects. The introduction of biomarkers in Phase II trials has 
not only improved the understanding of the biology of disease but also the molecular mechanisms of action 
of the drug candidate, helping in the identification of patients that are more likely to respond to the new 
treatment. However, to obtain useful information in a timely fashion, the selection of the biomarker is a 
crucial aspect. In cancer treatment, for instance, there are a few successful examples regarding the 
introduction of biomarkers in Phase II trials: trastuzumab for HER-2-positive breast cancer; and imatinib 
mesylate for BCR-ABL-positive chronic myelogenous leukemia, for details see. 
Phase III trials are usually multicenter, placebo-controlled randomized studies, including several hundred 
to a thousand subjects. At this stage, the aim is to collect more evidence about drug safety and effectiveness 
and long-term tolerability. These data are crucial for the approval and registration 4, 6 and 24. Phase IV 
corresponds to post-marketing studies after the drug has been approved aiming to strengthen data 
concerning long-term effects of the drug on morbidity and mortality. 
The use of imaging in clinical studies, whether only in the phase of proof-of-concept (Phase I) or in 
subsequent clinical studies, will depend not only on the disease but also on the quality of the imaging 
biomarker as well as the available resources. If imaging represents an added value for disease diagnosis, 
shorter studies including fewer patients would be feasible, which would potentially lead to considerable 
savings as a result of a shorter time-to-market. Although efforts have been made to approve more imaging 
biomarkers, the FDA's critical path initiative might be considered as an example 25, 26 and 27, currently 
there is still no imaging biomarker accepted as a surrogate endpoint, because validation has been very 
challenging. With the joint effort of regulatory agencies, academia and industry, perhaps in the future 
imaging biomarkers might serve as surrogate endpoints in clinical trials. More importantly, there is an 
urgent need to reduce the gap between clinical practice and regulatory requirements. The utilization of 18F-
FDG is a good example of such a gap, because it is widely used for tumor response evaluation but it is not 
approved by the regulatory agencies as a surrogate endpoint for clinical studies. More recently, 18F-FLT 
has been used to characterize the transport of nucleosides as a measure of cellular proliferation, providing 
valuable information about drug efficacy 30 and 31. 
Imaging modalities in the drug development process 
Over the past decade, imaging has been applied at several stages of drug discovery owing to the tremendous 
advantages arising from of its use. Particularly, in vivo functional imaging ( Box 2) provides a unique 
opportunity for studying disease noninvasively and, in many cases, quantitatively at the molecular level, 
along with the ability to monitor disease progression or response to treatment efficiently and repeatedly. 
The introduction of functional imaging in drug development at preclinical and clinical stages allows the 
shortening of the project length, improving the level of confidence in the results while reducing the inherent 
costs (increasing the revenues and cost-effectiveness). By contrast, the assessment of some important 
parameters is only possible through the use of functional imaging. Some examples are the time on target as 
well as the quantitative biodistribution and the inherent kinetic data, which are important for dosage 
optimization and dose frequency. 
 
  
At the preclinical stage, the most commonly used imaging modalities have been PET, single-photon 
emission computed tomography (SPECT), OI, computed tomography (CT), magnetic resonance imaging 
(MRI), magnetic resonance spectroscopy imaging (MRSI) and ultrasounds. With the exception of optical 
imaging, where clinical applications are still modest and not routinely used, all the other techniques have 
the advantage of being used in the diagnosis and follow-up of human diseases, easing the correlation 
between preclinical and clinical data (bench-to-bedside model). 
The perfect imaging modality (i.e. providing simultaneously high sensitivity, specificity, temporal and 
spatial resolution) does not exist. In many ways, the existing imaging technologies provide complementary 
information about the biological processes being studied; the reason why multimodality devices have 
definitely gained a huge popularity over the past years. In fact, nowadays, it is more and more common in 
daily practice to use two or more imaging modalities to study a (patho) physiological process adequately in 
the preclinical and the clinical context. The decision to choose one imaging modality over another will 
depend on the resources available as well as the type of information needed. In this paper, we provide an 
overview of the main in vivo imaging modalities that have major impacts on drug development, with a 
particular emphasis on nuclear modalities, owing to their high sensitivity and temporal resolution, and look 
out for the state-of-the-art hybrid imaging modalities such as PET/MRI, PET/CT and SPECT/CT/MRI 
combinations. 
Imaging biomarkers 
The FDA, EMA and the pharmaceutical industry have already recognized that the use of imaging 
biomarkers in the future could have a key role in accelerating drug development and lowering costs (namely 
by eliminating poor candidate drugs earlier in the development process). The number of available molecular 
imaging and contrast agents is increasing. This trend also applies to those approved by the FDA 
(http://www.ncbi.nlm.nih.gov/books/NBK5330/). The purpose of using imaging biomarkers early in 
clinical trials is to gather evidence in support of moving to larger and expensive trials, by demonstrating, 
for instance, that the drug candidate binds to the intended receptor or crosses the blood–brain barrier. 
Imaging biomarkers can be useful in a variety of applications such as a diagnostic tool for a symptomatic 
disease or as a screening tool to identify a disease not yet symptomatic or even as a follow-up tool to 
evaluate disease progression. Many biomarkers such as those used in nuclear applications have the 
advantage of not only providing structural information but also quantitative data concerning organ and/or 
tumor metabolism and function. Moreover, this kind of biomarker provides unique selectivity and 
sensitivity to measure drug interactions with specific pathways. As depicted in Fig. 3, 2-deoxy-2-
[18F]fluoro-D-glucose (18F-FDG), an analog of the glucose molecule, is a widely used PET imaging 
biomarker for assessing tumor metabolism. In the same panel, a SPECT tracer (99mTc-exendin-4) was used 
to determine the efficacy of streptozotocin in insulinoma treatment. Imaging is also useful in areas such as 
inflammation detection (Fig. 3), in which the efficacy of an anti-inflammatory drug can be evaluated by 
bioluminescence. The main advantage of molecular imaging biomarkers is the possibility to measure 
activity at the site of action (e.g. receptor occupancy) in a noninvasive way, allowing longitudinal studies 
to be performed in a very convenient, practical and cost-effective way. 
 
 Figura 3. Examples of some molecular imaging modalities in the characterization of tumor biology (a) 
and in the evaluation of drug effects over the target (b,c). (a) Tumor heterogeneity depicted by 2-deoxy-2-
[18F]fluoro-d-glucose (18F-FDG), a biomarker for clona selection, tumor stem cell and biology-modifier 
drug studies. Images were acquired in a positron emission tomography/molecular resonance imaging 
(PET/MRI) scan (NanoScan, Mediso, Hungary), 50 min after the intravenous injection of 18F-FDG 
(3.5 MBq) in a systemic mouse leukemia model. MRI acquisition was T2-weighted. Both imaging 
modalities show the presence of a highly complementary pattern of heterogeneous tumor tissue (white 
arrows). (bi,ii) Whole body single-photon emission computed tomography and computed (SPECT/CT) 
images (NanoScan SPECT/CT, Mediso, Hungary) of two male C57Bl6 mice were acquired, after the 
intravenous injection of 24 MBq of 99mTc-exendin-4, glucagonlike peptide-1 (GLP-1) receptors ligand. On 
the left, maximum intensity projection is shown and, on the right, a sagittal slice. (bi) Healthy mouse 
depicting 99mTc-exendin-4 accumulation in the pancreatic beta cells (white arrows). (bii) Streptozotocin-
treated mouse, showing no accumulation of 99mTc-exendin-4 in pancreatic beta cells. The kit for 
radiolabeling exendin-4 was kindly provided by Professor Fan Wang, Peking University Medical Isotopes 
Research Center, Beijing, China. (c) Bioluminescence imaging (IVIS100 system) using luminol assay for 
myeloperoxidase activity, showing local inflammation in the intestine in an induced inflammatory bowel 
disease (IBD) mouse model. Control is shown on the left. On the right, an animal treated animal with an 
anti-inflammatory small molecule C142 developed at Avidin, Szeged, Hungary, is shown. 
 
Molecular imaging has been applied to drug development aiming to improve disease characterization and 
early evaluation of drug efficacy and safety, drug pharmacokinetic profile characterization, image drug 
distribution in the target and assessment of target function. Many compounds are eventually selected for 
their excellent target binding and pharmacodynamic effects, the possibility to influence selected signal 
transduction pathways and other biological control processes. However, there are specific traits that allow 
the prediction of a potential failure in the development process that can be assessed using modern and 
advanced qualitative and/or quantitative imaging methodologies. Possible examples could be the in vivo 
imaging of transport over barriers in an organism-wide context and/or tracking known traits of toxicities 
such as cardio, liver or kidney toxicities. 
PET and SPECT 
The underlying principle of PET and SPECT modalities resides in the use of tracer amounts of radioactive 
compounds to produce biodistribution images of the drug candidate and/or the resulting effect on organ or 
body function. This requires two distinct approaches: in the first case, the drug candidate must be labeled 
with a suitable radionuclide that does not significantly change the structure of the original molecule; 
whereas in the second case, the drug candidate is administered and its effect on organ function or tumor 
size and metabolism can be assessed using molecular imaging biomarkers that accumulate in the organs 
under study (target organs). PET and SPECT radionuclides have distinct physical properties, mainly related 
to the type of emission and energy: the first group emits positrons that, after annihilation by electrons, 
generate two high energy photons (511 keV); the latter group emits one photon per decay, usually with 
much lower energy (25–250 keV). In both cases, the emitted photons will be detected by scintillation 
crystals, producing light that will be used to obtain electronic signals. Images are then formed, representing 
the biodistribution of the radiotracers. In the case of positron emitters, because two high energy photons 
are originated, PET imaging requires the placement of detectors on opposite sides of the emitting source to 
detect the coincident photons simultaneously. Currently, PET scanners are composed of detector blocks, 
assembled in a full ring configuration gantry. The scintillation material of PET detectors is coupled to a 
photomultiplier tube (or avalanche photodiode) to produce electrical pulses, the amplitude of which is 
proportional to the energy of the incident photon. The signal is then amplified and analyzed to check 
whether they fall inside the predefined energy window centered at 511 keV. Moreover, a parallel signal 
path is propagated from the amplifier to a timing single-channel analyzer on the opposite detector to 
determine if the detected photons originated from the same annihilation event. If the pulses are detected in 
the predefined temporal window (8–12 ns in most cases) and the energy criteria are met, then the event is 
considered coincident and recorded to form the final image. 
Single or multiple images (including whole body) can be acquired without increasing the amount of 
radiotracer given to the subject or the radiation exposure. Recently, more intercompatible albeit less stable 
silicon-based sensors have been paving the way for breakthrough future combinations of methodologies. 
In the field of neuroscience, for instance, measurements of receptor occupancy with radiotracers usually 
involve the acquisition of a ‘baseline’ [i.e. scanning with an adequate radiotracer, for instance D2 receptor 
occupancy imaged with 11C-raclopride or brain metabolism depicted with 18F-FDG – this scan takes place 
before treatment with the candidate drug to characterize the basal state and is then repeated during or after 
one (or several) session(s) of drug administration] PET or SPECT scan and a MRI scan providing anatomic 
references. Then, the subject is treated with the drug candidate (single- or multi-dose regimen), followed 
by the acquisition of another PET or SPECT scan, often paralleled by blood sampling to determine plasma 
pharmacokinetics of the drug, allowing measurement of the displacement of tracer by the drug candidate. 
The chance to perform these studies in species ranging from mice to non-human primates, prior to the first 
human administration, makes it possible not only to establish prioritization of which candidate drug will go 
forward to the clinical studies but also to confirm the dose range and regimen, or even to discontinue a 
research program if insufficient concentration of the drug accumulates in the desired target 35 and 38, or 
even if maximal receptor occupancy has been reached but no efficacy is observed. At this stage the kinetics 
of receptor occupancy by the candidate drug should be fully understood (including maximal occupancy) 
and compared with drug efficacy observed in preclinical models to establish targets for clinical studies. A 
common example that is usually given is the study of neurokinin 1 (NK1) receptor occupancy by PET, 
which provided an understanding about the relationship between the blood levels of aprepitant (an 
antagonist of the NK1 receptor) and the receptor occupancy. This drug was thought to be effective as an 
antidepressant and only at Phase III trials was PET introduced to image normal subjects and patients under 
treatment. Imaging revealed that the aprepitant dosing regimens provided continuously high levels of NK1 
receptor blockade but no efficacy. 
Another approach that has been explored to a lesser degree so far is to label the drug candidate directly with 
a suitable radionuclide, collecting information about the pharmacokinetic profile of the drug candidate  such 
as the percentage of the injected dose that accumulates in the organs, its regional distribution and kinetics 
as well as the relationship with plasma levels. Even though this might be a valuable approach, it could see 
some challenges related to the feasibility, complexity and optimization of the labeling procedure. Moreover, 
although the uptake of the drug by the target organ can be imaged and quantified, it might not tell enough 
about a drug's action on the target site. For example, the antipsychotic drug clozapine was labeled with 
carbon-11 and its regional brain distribution was imaged by PET. Although a high level of striatal uptake 
was observed, it was not clear whether the drug bound to serotonine (5-HT2), dopamine (D2) or cholinergic 
receptors. Later on, through the use of target-specific radioligands, it was possible to study the ability of 
clozapine to compete with the receptors and, only then, to characterize its pharmacologic profile. In fact, 
PET and SPECT have been extensively used to study antipsychotic drugs in the preclinical and clinical 
context, not only due to the availability of suitable dopamine D2 receptors but also to the high sensitivity 
of these imaging modalities 44 and 45. It is known that a certain level of occupancy is required to achieve 
efficacy and that levels that are too high will induce extra-pyramidal side effects. Imaging has played a 
relevant part in providing data to establish the dose required to maximize efficacy while minimizing side 
effects. Of paramount importance is the fact that the amount of administered PET or SPECT ligands is far 
from the pharmacologic doses (high specific activity), allowing safe image acquisition without radiotracer 
interference on the biological processes under study (because tracer doses are in the range of nano- or 
micro-grams, presenting similar pharmacokinetic characteristics but in the range of no therapeutic effects, 
whereas pharmacological doses are in the range of milligrams or grams and associated with 
pharmacodynamic effects). Additionally, a good molecular imaging ligand must have other properties such 
as: high affinity for the receptor of interest; ability to reach the equilibrium within the time-frame for the 
measurement, in order to determine the binding potential; low nonspecific binding, allowing background 
noise to be kept as low as possible; high selectivity for the target; and a ‘simple-as-possible’ radiochemistry, 
which allows its use in a multicentric study at reasonable cost. Although not having in vivo microscopic 
spatial resolution, nuclear imaging has a high sensitivity, detecting less than 10−1 to 10−12 M of tracer 
molecules and 10−15 M target protein concentrations per mg of imaged tissue (for PET) in vivo. Preclinical 
SPECT has submillimeter (0.3–0.5 mm) resolution, and preclinical PET has now also entered the 
submillimeter range (unpublished). The clinical counterparts have about 10–15 mm and 4–5 mm, 
respectively. Moreover, an each-day wider range of radioactive probes is available for nuclear imaging, 
allowing quantitative data to be obtained, without depth penetration limitations. Owing to its higher 
sensitivity, PET imaging might be more accurate for quantification purposes. By contrast, a great advantage 
of PET is that the most common and relevant biological elements, such as carbon, oxygen, nitrogen and 
fluorine, have positron emitter isotopes, implicating a much better access to labeled biologically active 
molecules, because they are easily attached via covalent bonds to an huge number of biochemical and drug 
structures, leading to a greater versatility in the development of PET biomarkers compared with the 
application of 99mTc (attached via bulky chelating linker groups) or 123I (which forms a biologically unstable 
bond with carbon). In fact, if the radioisotope can directly substitute the stable isotope of a certain molecule, 
the molecular structure and consequently the chemical properties will be almost identical. 
The major advantages of SPECT are the possibility to use and detect a variety of radioactive agents based 
on radioisotopes with different energies (making it possible to image simultaneously two or more molecular 
pathways), a relatively simple and stable chemistry allowing the synthesis of ligands on site and their 
relatively long physical half-lives (ranging from hours to days), making them easily accessible to many 
research groups and suitable to be used in such investigational contexts where the need for longer periods 
for data acquisition is verified; for instance, slower kinetic processes of antibody and fragment 
accumulation 47 and 50. 
As mentioned, PET radionuclides are usually isotopes of carbon, fluorine, oxygen and nitrogen occurring 
abundantly in tissues, but they have shorter physical half-lives (ranging from minutes to hours), ideally 
requiring an ‘on-site’ solution for radiotracer production. In the case of the most widely available 
fluorinated compounds (fluorine-18) they are easier to transport as a result of the physical half-life of 18F 
(110 min). Although the use of carbon-11 compounds might be compatible with local solutions, it is most 
frequently limited to laboratories with an on-site cyclotron (11C half-life: 20 min) with even harder 
conditionings applying to nitrogen-13 (half-life: 10 min) and oxygen-15 (half-life: 2 min). Ideally, the 
physical half-life of the radionuclide should be comparable with the biological half-life of the kinetic 
process to be quantitated and visualized, meaning that the use of controlled delivery formulations, 
liposomes, particulate drugs and antibody-based solutions will require longer half-life nuclides for 
radiolabeling in PET. These cyclotron products could be zirconium-89 and iodine-124 (and to a lesser 
extent technetium-94 m) where one of the main advantages of PET concerning biogenic isotopes is lost but 
better quantitation and kinetic modeling characteristics are maintained. Table 1 summarizes the main 
radionuclides used in PET and SPECT imaging. Specific activity is a very important parameter, 
corresponding to the proportion of radioactive (probe) atoms to the whole amount of the atoms of the 
element applied for radiolabeling the test compound or biomarker molecule. Therefore, the specific activity 
of the radiolabeled molecule (final compound) will be determined not only by the specific activity of the 
element but also by the labeling efficiency of the molecule, which is indeed a key issue for accurate 
measurements. As shown in Table 1, SPECT radionuclides have greater specific activity compared with 
PET tracers. Higher specific activity probes are essential to obtain as low as possible injected test compound 
masses, to ensure pharmacodynamic inertness of the imaging process. 
 
 
  
Other imaging modalities 
Other imaging modalities can complement data from nuclear techniques. Morphologic techniques such as 
CT and MRI have been particularly useful owing to the lack of anatomic detail of nuclear modalities (Fig. 
2). Computed tomography is a morphological imaging technique that measures differences in tissue density, 
being particularly useful for the study of bone structures and lung imaging. A typical CT system consists 
in an X-ray tube and an X-ray detector assembled in opposite positions in a rotating gantry. X-rays 
traversing the subject deposit energy in an inverse proportion to the electron density of the body tissue; the 
remaining energy is detected by the detector. The main advantage of CT is the high spatial resolution (30–
100 μm for in vivo preclinical devices and 400–600 μm in high performance clinical scanners). Besides 
having low sensitivity, the main drawback of CT is related to radiation burden for the subjects involved in 
the procedures, even more crucial when longitudinal studies will be conducted. CT has an established role 
in the assessment of tumor response to cytotoxic therapies. The size of tumors is measured using either the 
sum of the perpendicular diameters or the sum of the largest diameters [response evaluation criteria in solid 
tumors (RECIST)], providing a morphologic evaluation of tumor growth and response to therapy. 
Additionally, using contrast agents, it might be possible to obtain some extra information related to tumor 
perfusion. 
MRI relies on magnetic properties of tissues and their interactions with strong external magnetic fields. 
Hydrogen nuclei (1H) from water are the most used in MRI, owing to their paramagnetic properties and 
abundance in the body. Briefly, the underlying principle is that, when a sample within a magnetic field is 
subjected to a radio-frequency pulse, protons absorb energy and generate a detectable signal during the 
relaxation phase which can be digitally encoded through magnetic field gradients to generate digital images. 
MRI is a very versatile imaging modality, providing morphological images with excellent contrast and 
spatial resolution (<50 μm for preclinical devices and 300 μm in ultra-high field experimental clinical 
devices), as well as information regarding tissue composition, perfusion, oxygenation, tissue elasticity, 
metabolism and detection of molecular probes within a single acquisition session without radiation 
exposure. One of these MRI modalities is designated as functional MRI (fMRI) or blood oxygen level 
dependent (BOLD) imaging, based on the distinct magnetic properties of oxyhemoglobin and 
deoxyhemoglobin, which might be considered particularly useful for brain activation studies. Additional 
parameters such as brain or tumor perfusion and vascular permeability can be assessed using dynamic 
contrast enhanced imaging (DCE-MRI), where an intravenous bolus injection of a contrast agent is detected 
during its first passage through the organs or the arterial spin labeling (ASL) in which the arterial blood 
water magnetization itself functions as an endogenous contrast agent. Nowadays, DCE-MRI is the most 
commonly used modality for the preclinical and early clinical evaluation of antiangiogenic agents. Some 
examples are Avastin® (bevacizumab, Roche), Nexavar® (sorafetinib, Pfizer), Sutent® (sutinib, Pfizer). 
Magnetic resonance spectroscopy (MRS) provides information about the concentration of certain chemicals 
in the organs and so far has been useful in brain studies for the quantification of N-acetyl aspartate, choline, 
creatine, myo-inositol, lactate, lipids, glutamine, glutamate and amino acids. However, compared with PET, 
MRI has a lower sensitivity (three to six orders of magnitude), requiring an amount of 10−3 to 10−5 M of 
imaging probe to be detected within a single voxel. The higher sensitivity of nuclear techniques makes them 
a unique approach when low density binding sites are the drug targets. 
OI includes a variety of techniques based on the use of a set of light sources and very sensitive detecting 
devices that capture the photons transmitted through tissues. To improve image contrast, targeted 
fluorescent or activatable probes were developed, making it possible to measure the activity of the chosen 
molecular targets. Imaging of such probes involves excitation at a certain wavelength and the detection of 
the specific signal emission at a significantly different wavelength. The most relevant OI techniques are 
bioluminescence, fluorescence and near infrared fluorescence imaging. In the context of fluorescence 
imaging, quantum dots (i.e. inorganic fluorescent semiconductor nanoparticles) are becoming increasingly 
popular. Overall, the most important advantages of OI are the high sensitivity, low cost, relatively high 
throughput and short acquisition time (typically 10–60 s), as well as the visualization of physiological and 
pathophysiological processes at the cellular and molecular level in vivo with high specificity. An additional 
advantage of OI is the fact that several probes with different spectral characteristics can be used for 
multichannel imaging. The main drawbacks of OI include: the limited transmission of light from tissues, 
which limits spatial resolution and the depth of imaging, resulting in a very limited signal quantification. 
Moreover, so far, OI has limited clinical application, but in the preclinical arena OI has been very useful in 
the detection and functional characterization of tumors through the application of fluorescence enzyme-
mediated probes that bind to proteases that are expressed by tumors (cathepsin, matrix metalloproteinases 
2 and 7 and caspase 1), as well as in the detection of infection and inflammation ( Fig. 3). 
The intrinsic limitations of each imaging modality (Table 2) have led to the idea of combining two or more 
modalities to image the same biological process in the same animal. Multimodality imaging provides 
complementary information upon the subject and/or pathophysiological process being studied. The most 
common are the combinations between high sensitivity and functional modalities, such as PET and SPECT, 
with high spatial resolution and morphological techniques, such as CT and MRI. The rationale underlying 
the preference for multimodal imaging using one or several types of devices (either single or dual-modality: 
PET/CT, SPECT/CT and PET/MRI the most used by order of relevance, or tri-modality: PET/SPECT/CT 
the most popular configuration, or even four-modality devices that are under study by some manufacturers) 
is multifactorial, and should consider the relevant issues for each specific case. In fact, there are pros and 
cons for each option and, if no single imaging modality can fulfill the research needs of drug development 
industry entirely, the access to multimodality might be obtained directly by hybrid imaging–when the same 
device uses distinct imaging modalities–and/or co-registration with other imaging modalities. Compact 
benchtop systems might be considered better, essentially because of their practical physical aspects (i.e. 
can be placed almost anywhere in a research laboratory) but also because of their increased easiness of use 
(normally presenting lower complexity that might allow newcomers to the field of imaging to be quickly 
autonomous in their operation) and higher cost:efficiency ratios (owing to the integration process); 
nevertheless, the final throughput might not be the most favorable (and this might be a very relevant issue 
when the number of subjects to be evaluated is considerable). In fact, multimodality imaging has been 
gaining notable popularity in the preclinical and in the clinical context. An increasing number of authors 
defend that, in the (near) future, multimodality imaging will be the prevailing concept of in vivo imaging 
13, 63 and 64. 
 
 
  
The decision for an imaging modality should be done taking into consideration firstly the question to be 
addressed and secondly the material conditions available, as well as possible logistic limitations relevant 
for the experimental procedures. Although the challenge of data translation from animals to humans is 
indeed a huge one, it can be more easily done if the chosen modalities (and respective imaging probes) for 
small animal imaging have clinical homology, thus reducing the gap between preclinical and clinical 
studies. Nuclear modalities (PET or SPECT), through the use of the radiolabeled form of the drug candidate 
at an early stage, provide valuable information about drug pharmacokinetics in a small group of rodents. 
Usually, the same studies are then held in a small group of humans and, if results between animal and 
human studies are similar, then the drug candidate is tested in larger populations of animals and finally in 
more humans. This demonstrates how imaging techniques and particularly nuclear modalities fill the gap 
between preclinical and clinical research. The requisites for imaging methods in translational medicine are 
well defined: the techniques must be quantitative, reproducible, specific, sensitive, applicable to clinical 
practice and safe. PET is the imaging modality that best meets all these requirements. Although SPECT has 
lower sensitivity and is based on less physiological probes, it might as well represent an interesting 
possibility, namely when the physiological process under study requires the use of radionuclides with 
longer half-lives. 
Examples of applications 
As mentioned in the previous sections, molecular imaging can play a part in multiple steps of drug 
development (i.e. disease characterization to drug target validation as well as the characterization of drug 
pharmacokinetic and pharmacodynamic profiles). The first key step in the drug development process is 
target selection; the role of molecular imaging here is to provide information about the presence of specific 
targets, their spatial and temporal distribution, as well as the effect resulting from the interaction between 
the drug and the target. One of the main challenges at this stage is to develop specific probes and 
amplification strategies to distinguish target signal from non-target (background) signal, which might be 
tricky for low target (subnanomolar) concentrations. There are some examples available in the literature 
describing the successful use of imaging in drug development, particularly in the fields of neurology and 
oncology. Nuclear techniques have long been used for the study of receptor expression and occupancy in 
central nervous system drug development 7 and 10. A significant number of receptor ligands have been 
labeled with 11C, 18F and 123I for the study of several receptor systems, especially dopaminergic and 
serotoninergic ones. Other target-specific probes have also been developed such as the near infrared 
fluorescent dye Cy5.5 and magnetic contrast agents such as iron oxide. Microbubbles that bind to vascular 
endothelial growth factor receptor 2 (VEGFR2) and αvβ3 integrin have been used in US imaging for tumor 
angiogenesis evaluation. 
Paclitaxel (a chemotherapeutic agent that inhibits mitosis) was labeled with 18F to characterize its 
pharmacokinetics and, because it is a substrate for the P-glycoprotein (Pgp) efflux pump, the dynamics of 
the pump and the consequences of multidrug resistance were also accessed. Moreover, through the use of 
imaging it was possible to understand that there are significant differences between brain and plasma 
kinetics. Gefvert et al. used 11C-raclopride and 11C-N-methyl-spiperone as ligands to show that the 
antipsychotic drug, quetiapine, despite its short half-life in plasma (2.5–5.0 h), has much a longer half-life 
in terms of receptor occupancy (10 h), which allowed changing the treatment regimen based on two-times 
a day dosing instead of three times (thought to be optimal based on plasma level data). 
The action of vortioxetine was assessed using 11C-N,N-dimethyl-2-(2-amino-4-
methylphenylthio)benzylamine (11C-MADAM) and 11C-WAY100635 for the quantification of 5-HTT and 
5-HT1A occupancy, respectively. Vortioxetine is a recently approved (September 2013) antidepressant for 
the treatment of major depressive disorders, acting by a combination of two mechanisms: receptor activity 
modulations and reuptake inhibition. Table 3 shows some examples of recently approved drugs where 
imaging was used during development phases. 
 
  
In the field of oncology, owing to its superior sensitivity, 18F-FDG has been the classical agent for 
glycolytic metabolism evaluation, because tumor uptake reflects the level of glucose transporter 1 
(GLUT1) expression and the enzymatic activity of hexokinase. During the approval process, all patients 
with gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) who responded to 
anticancer therapy exhibited metabolic changes that preceded, by weeks or months, a significant decrease 
in tumor size seen on CT [71]. 
Concluding remarks 
Over the past decade, molecular imaging has gained increasing acceptance by the academic and industry 
communities regarding drug discovery and development. It has been useful in the acquisition of a deeper 
knowledge of biology regarding a variety of diseases, allowing the design of better candidate drugs in the 
identification and validation of new therapeutic targets, in the selection of candidate drugs that must move 
forward to the clinic or those where research should be stopped and in the establishment of dose range 
and regimens. Imaging has brought modern drug development to a superior level, not only by providing a 
deeper understanding of normal physiology, molecular mechanisms of disease and drug effects but also 
by allowing significant savings (in terms of time and resources). Molecular imaging in particular has 
driven not only the development of safer and innovative drugs but also strengthens the concept of 
personalized medicine. 
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